Home » Stocks » Endologix

Endologix, Inc. (ELGX)

Jul 16, 2020 - ELGX was delisted due to bankruptcy and now trades as ELGXQ
Stock Price: $0.220 USD 0.000 (0.00%)
Updated Jul 15, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 4.22M
Revenue (ttm) 136.27M
Net Income (ttm) -60.85M
Shares Out 19.17M
EPS (ttm) -3.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 15, 2020
Last Price $0.220
Previous Close $0.220
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.220 - 0.280
Day's Volume 0
52-Week Range 0.220 - 7.100

More Stats

Market Cap 4.22M
Enterprise Value 156.02M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.17M
Float 14.12M
EPS (basic) -3.07
EPS (diluted) -3.16
FCF / Share -1.28
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 343,574
Short Ratio 0.91
Short % of Float 2.02%
Beta 0.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.03
PB Ratio 0.10
Revenue 136.27M
Operating Income -46.74M
Net Income -60.85M
Free Cash Flow -25.68M
Net Cash -151.80M
Net Cash / Share -7.92
Gross Margin 66.84%
Operating Margin -34.30%
Profit Margin -44.60%
FCF Margin -18.85%
ROA -9.82%
ROE -167.38%
ROIC -17.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

$3.94*
(1,691% upside)
Low
0.88
Current: $0.220
High
7.00
Target: 3.94
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue14315618119315414813210683.4267.25
Revenue Growth-8.37%-13.63%-6.1%25.59%4.08%11.59%24.83%27.01%24.04%-
Gross Profit91.0991.9212112410210699.5180.6664.6752.22
Operating Income-42.55-68.19-41.82-95.07-52.91-29.15-10.37-21.89-18.42-4.22
Net Income-64.76-79.71-66.40-155-50.42-32.42-16.07-35.77-28.7310.65
Shares Outstanding16.858.798.338.106.776.526.265.985.664.89
Earnings Per Share-3.84-9.07-7.97-19.10-7.50-5.00-2.60-6.00-5.102.10
Operating Cash Flow-29.57-38.61-35.40-72.81-31.09-26.331.49-18.53-22.38-4.11
Capital Expenditures-0.46-0.60-1.17-2.80-4.19-13.46-2.86-2.24-3.03-0.86
Free Cash Flow-30.03-39.22-36.57-75.60-35.28-39.80-1.37-20.77-25.42-4.97
Cash & Equivalents42.7624.7360.6049.1117786.6712645.1220.0438.19
Total Debt19419822517716870.4167.10---
Net Cash / Debt-152-173-165-1289.5716.2659.3645.1220.0438.19
Assets307293365360331248256165130134
Liabilities24325329024722812415270.6353.6940.47
Book Value63.8639.6575.0611310312410594.4776.5793.90
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Endologix, Inc.
Country United States
Employees 488
CEO John Onopchenko

Stock Information

Ticker Symbol ELGX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: ELGX
IPO Date June 20, 1996

Description

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. On July 5, 2020, Endologix, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with TriVascular Sales LLC.